Methylphenidate for the Treatment of Apathy in Alzheimer Disease: Prediction of Response Using Dextroamphetamine Challenge
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Apathy is a common behavioral symptom of Alzheimer's disease (AD), being present in up to 70% of patients. Apathy in AD and non-AD populations has been associated with dysfunction in the dopaminergic brain reward system, suggesting that pharmacotherapeutic targeting of this system may be an effective treatment for apathy in AD. We therefore performed a randomized, double-blind, placebo-controlled crossover trial of methylphenidate in a sample of 13 apathetic AD patients (6 men, 7 women; age mean 77.9 years [SD, 7.8 years]; Mini Mental Status Examination score, 19.9 [SD, 4.7]). Patients were treated with methylphenidate (10 mg PO twice a day) or an identical placebo in two 2-week phases separated by a 1-week placebo washout. All patients participated in a dextroamphetamine challenge test (one 10-mg oral dose) before treatment with methylphenidate to gauge the functional integrity of the dopamine brain reward system. Overall, patients demonstrated greater improvement with methylphenidate compared with placebo according to Apathy Evaluation Scale total change scores (end of treatment - baseline: Wilcoxon Z = -2.00; P = 0.047). However, a significantly greater proportion of patients experienced at least 1 adverse event with methylphenidate compared with placebo (3 vs 1; chi = 4.33, P = 0.038). Two patients experienced serious adverse events with methylphenidate, consisting of delusions, agitation, anger, irritability, and insomnia, which resolved upon discontinuation of the medication. Response to methylphenidate was associated with increases in inattention on a continuous performance task after dextroamphetamine challenge. Psychostimulants may be effective in treating features of apathy in AD, and dopaminergic changes may predict response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Tremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N., & Busto, U. E. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.409 · Cited by 229
Self-citationHill, H. E., Haertzen, C. A., Wolbach, A. B., & Miner, E. J. (1963) · Psychopharmacologia · doi:10.1007/bf02584089 · Cited by 159
A SPECT study of apathy in Alzheimer's disease
Lanctôt, K. L., Moosa, S., Herrmann, N., Leibovitch, F. S., Rothenburg, L., Cotter, A., & Black, S. E. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000103633 · Cited by 126 · cited 1×
“We have recently demonstrated that dysfunction in brain areas included in the BRS is related specifically to symptoms of apathy in a sample of mild-to-moderate AD patients.(16) Pharmacotherapeutic targeting of the BRS may therefore improve apathy in AD.”
BackgroundKrause, J., la Fougere, C., Krause, K.-H., Ackenheil, M., & Dresel, S. H. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0602-x · Cited by 84 · cited 1×
“Interestingly, methylphenidate treatment response in adults with attentiondeficit/hyperactivity disorder was significantly reduced among patients with reduced dopamine transporter availability.(46) Thus, it is possible that both age- and disease-related declines in dopaminergic function may contribute to a limited abi…”
Background
Cited by
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders
Robert, P., Onyike, C. U., Leentjens, A. F. G., Dujardin, K., Aalten, P., Starkstein, S., Verhey, F. R. J., Yessavage, J., Clement, J. P., Drapier, D., et al. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.09.001 · Cited by 619
Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment
Pagonabarraga, J., Kulisevsky, J., Strafella, A. P., & Krack, P. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00019-8 · Cited by 549
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., & Liu, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00175 · Cited by 268
Metadata
- Authors
- Herrmann, N., Rothenburg, L. S., Black, S. E., Ryan, M., Liu, B. A., Busto, U. E., & Lanctôt, K. L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-06
- Volume
- 28
- Issue
- 3
- Pages
- 296-301
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2052830713
- Cited by
- 147
- References
- 5
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylphenidate for the Treatment of Apathy in Alzheimer Disease: Prediction of Response Using Dextroamphetamine Challenge. https://app.cochat.ai/papers/10.1097/jcp.0b013e318172b479
- The paper
- Herrmann, N., Rothenburg, L. S., Black, S. E., Ryan, M., Liu, B. A., Busto, U. E., & Lanctôt, K. L. (2008). Methylphenidate for the Treatment of Apathy in Alzheimer Disease: Prediction of Response Using Dextroamphetamine Challenge. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318172b479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.